Impact of Phase 2b strategies on optimization of drug development programs

Christopher Jennison, Zoran Antonijevic, Jim Bolognese, Carl-Fredrik Burman, Christy Chuang-Stein, Martin Kimber, Olga Marchenko, Nitin Patel, Jose Pinheiro

Research output: Chapter in Book/Report/Conference proceedingChapter

Original languageEnglish
Title of host publicationOptimization of Pharmaceutical R&D Programs and Portfolios: Design and Investment Strategy
Place of PublicationHeidelberg
PublisherSpringer
Pages83-103
ISBN (Electronic)978-3-319-09075-7
ISBN (Print)978-3-319-09074-0
DOIs
Publication statusPublished - 2015

Cite this

Jennison, C., Antonijevic, Z., Bolognese, J., Burman, C-F., Chuang-Stein, C., Kimber, M., ... Pinheiro, J. (2015). Impact of Phase 2b strategies on optimization of drug development programs. In Optimization of Pharmaceutical R&D Programs and Portfolios: Design and Investment Strategy (pp. 83-103). Heidelberg: Springer. https://doi.org/10.1007/978-3-319-09075-7_6

Impact of Phase 2b strategies on optimization of drug development programs. / Jennison, Christopher; Antonijevic, Zoran; Bolognese, Jim; Burman, Carl-Fredrik; Chuang-Stein, Christy; Kimber, Martin; Marchenko, Olga; Patel, Nitin; Pinheiro, Jose.

Optimization of Pharmaceutical R&D Programs and Portfolios: Design and Investment Strategy. Heidelberg : Springer, 2015. p. 83-103.

Research output: Chapter in Book/Report/Conference proceedingChapter

Jennison, C, Antonijevic, Z, Bolognese, J, Burman, C-F, Chuang-Stein, C, Kimber, M, Marchenko, O, Patel, N & Pinheiro, J 2015, Impact of Phase 2b strategies on optimization of drug development programs. in Optimization of Pharmaceutical R&D Programs and Portfolios: Design and Investment Strategy. Springer, Heidelberg, pp. 83-103. https://doi.org/10.1007/978-3-319-09075-7_6
Jennison C, Antonijevic Z, Bolognese J, Burman C-F, Chuang-Stein C, Kimber M et al. Impact of Phase 2b strategies on optimization of drug development programs. In Optimization of Pharmaceutical R&D Programs and Portfolios: Design and Investment Strategy. Heidelberg: Springer. 2015. p. 83-103 https://doi.org/10.1007/978-3-319-09075-7_6
Jennison, Christopher ; Antonijevic, Zoran ; Bolognese, Jim ; Burman, Carl-Fredrik ; Chuang-Stein, Christy ; Kimber, Martin ; Marchenko, Olga ; Patel, Nitin ; Pinheiro, Jose. / Impact of Phase 2b strategies on optimization of drug development programs. Optimization of Pharmaceutical R&D Programs and Portfolios: Design and Investment Strategy. Heidelberg : Springer, 2015. pp. 83-103
@inbook{75598c9ffd324102a538a841f047ae52,
title = "Impact of Phase 2b strategies on optimization of drug development programs",
author = "Christopher Jennison and Zoran Antonijevic and Jim Bolognese and Carl-Fredrik Burman and Christy Chuang-Stein and Martin Kimber and Olga Marchenko and Nitin Patel and Jose Pinheiro",
year = "2015",
doi = "10.1007/978-3-319-09075-7_6",
language = "English",
isbn = "978-3-319-09074-0",
pages = "83--103",
booktitle = "Optimization of Pharmaceutical R&D Programs and Portfolios: Design and Investment Strategy",
publisher = "Springer",

}

TY - CHAP

T1 - Impact of Phase 2b strategies on optimization of drug development programs

AU - Jennison, Christopher

AU - Antonijevic, Zoran

AU - Bolognese, Jim

AU - Burman, Carl-Fredrik

AU - Chuang-Stein, Christy

AU - Kimber, Martin

AU - Marchenko, Olga

AU - Patel, Nitin

AU - Pinheiro, Jose

PY - 2015

Y1 - 2015

UR - http://dx.doi.org/10.1007/978-3-319-09075-7_6

U2 - 10.1007/978-3-319-09075-7_6

DO - 10.1007/978-3-319-09075-7_6

M3 - Chapter

SN - 978-3-319-09074-0

SP - 83

EP - 103

BT - Optimization of Pharmaceutical R&D Programs and Portfolios: Design and Investment Strategy

PB - Springer

CY - Heidelberg

ER -